Ceftriaxon
Phase 2Small molecule
Ceftriaxon is one of 45 small molecule programs targeting Urinary Tract Infection. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
163 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Maxipime
PfizerPhase 3
Medrol
PfizerPhase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Prulifloxacin
Merck & Co.Phase 3
Piperacillin/tazobactam
PfizerPhase 3
Amoxicillin/clavulanate Potassium
Johnson & JohnsonPhase 3
Blujepa
GGlaxo Dba Glaxosmithkline
Phase 3
Imipenem+cilastatin/relebactam
Merck & Co.Phase 3
Amoxicillin/clavulanate
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Shigellosis1 trial
Tebipenem Trial in Children With Shigellosis
Active, not recruiting·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 2·NCT05121974·132 enrolled
Pregnancy1 trial
Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
Recruiting·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group··NCT07207876·110 enrolled
Azithromycin1 trial
Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea
Completed·—·Phase 4·NCT06090565·161 enrolled
Urinary Tract Infection1 trial
Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis
Recruiting·—·Phase 1·NCT05761405·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ceftriaxon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details